Auremune

The project is developing a completely new and unique product that has the potential to radically change the allergy market. By providing a new preventive allergy vaccine to be used early in life that is educating the immune system, we can provide the next generation of children with a broad and life-long protection against allergy development.

Auremune Stories

2010

Aug
16
During the last 12 months, the incubator at Vera Sandbergs Allé has been full of activity as 35 entrepreneurship students from CSE (Chalmers School of Entrepreneurship) and GIBBS (Göteborg International Bioscience Business School) has developed business plans for their idea providers business ideas. Now they face the challenge of leaving the incubator and take the final steps towards creating a venture capable of attracting venture capital. Read more about the 12 projects and their process this last year.
May
5
The Encubator Business Review took place this week where all of the projects, currently in the incubator, presented their business ideas and business plans in front of an audience and a panel of professionals. The two days resulted in five winners of SEK 10 000 each.
Mar
24
The Allergy Vaccine Project is going to Beijing, China to attend the BIT Life Sciences’ Annual World Vaccine Congress, held during the 24-26 of March.

2009

Dec
18
Auremune allergy vaccine project was awarded 320 000 SEK from GöteborgBIO and Sahlgrenska Science Park for verification of an exciting new way of preventing allergy.
Nov
27
On the 15th and 16th of December you will have the opportunity to partake in nine different presentations from our students, and hear how they respond to the feedback they receive from the panel of invited professionals.
Auremune develops a unique vaccine against allergies.
Annika Bergström
Sara Lorentzon
Lan Yang
Lars Lanhed / Masonit
Auremune is an Encubator Start-up Project from GIBBS class of 2010.
Auremune develops a unique vaccine against allergies.
Biotech
Vera Sandbergs Allé 8, Gothenburg